Harlan Krumholz
Latest contributions
New evidence for coronary revascularisation
21 May 2026 – From EuroPCR 2026
This session highlights new evidence in coronary revascularisation, including the role of CT-derived virtual stenting for procedural optimization, left ventricular unloading during complex PCI, long-term outcomes of FFR-guided PCI versus medical therapy, Impella CP support in high-risk PCI, and comparative results of PCI versus CABG in...
Major Late-Breaking Trials from EuroPCR 2026
20 May 2026 – From EuroPCR 2026
This session presents major late-breaking trials from EuroPCR 2026, reviewing contemporary evidence on coronary revascularization in TAVI patients, long-term outcomes of PCI versus CABG for left main disease, and comparative effectiveness of LAA closure versus NOAC in atrial fibrillation across age groups, with clinical practice implications.
Pharmacotherapy coronary interventions: new insights
22 May 2025 – From EuroPCR 2025
Stay abreast of new insights in pharmacotherapy for coronary interventions with a focus on optimizing patient outcomes. Topics include ticagrelor monotherapy in chronic coronary syndrome post-PCI, analysis of multiple events in high bleeding risk patients from the MASTER DAPT trial, effects of beta-blocker interruption in MI...
Hotline TAVI 2: outcomes with new and established devices
21 May 2025 – From EuroPCR 2025
Review outcomes of new and established TAVI devices through pooled analyses and multicenter studies. Topics include comparisons of balloon-expandable valves, intra- versus supra-annular self-expanding valves, and insights from the ACURATE IDE and ACURATE prime studies.
